

1 **Brain cerebral blood flow with MRI-visible enlarged** 2 **perivascular space in adults**

3 *Chunyan Yu¹,M.D; Baijie Wang²,M.D; Qiyuan Sun¹,M.D; Huiyan Huo¹,M.D; Lingyan*
4 *Zhang^{3*}, PhD; Hongyan Du^{1*},B.S*

5 *¹Department of Medical Imaging, Longgang Central Hospital of Shenzhen, Shenzhen*
6 *518116, P.R. China*

7 *²Department of Medical Imaging, National Cancer Center/National Clinical*
8 *Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy*
9 *of Medical Sciences and Peking Union Medical College, Shenzhen 518100, P.R.*
10 *China*

11 *³Lab of Molecular Imaging and Medical Intelligence, Department of Radiology,*
12 *Longgang Central Hospital of Shenzhen, Shenzhen Clinical Medical College,*
13 *Guangzhou University of Chinese Medicine, Longgang Central Hospital of Shantou*
14 *University Medical College , Shenzhen 518116, P. R. China*

15 **Correspondence to: Hongyan Du, Longgang Central Hospital of Shenzhen, Shenzhen*
16 *city, Guangdong province, China; Email address:Duhongyan1212@163.com*

17 *Lingyan Zhang, Street address: 6082 Longgang Avenue, Longgang District, Shenzhen*
18 *city, Guangdong province, China; Email address: 18819818005@163.com*

19 **Running Title:** Brain CBF in adults with MRI-visible enlarged perivascular space

20 **Word count (abstract):** 278

21 **Number of references:** 43

22 **Number of figures:** 5

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **Number of tables: 2**

24 **Total words:5317**

25

26

27 **Abstract**

28 **Objective:** To explore the correlation between enlarged perivascular spaces (EPVS)
29 in the basal ganglia (BG-EPVS) and centrum semiovale (CSO-EPVS) and changes in
30 adult brain cerebral blood flow (CBF).

31 **Methods:** This cross-sectional single-center cohort study included individuals with
32 varying degrees of EPVS, divided into the BG and CSO based on the established
33 rating scale. Subsequently, the arterial spin labeling (ASL) sequence and its post-
34 processing operation were utilized to obtain CBF values for different grades of BG-
35 EPVS and CSO-EPVS. Logistic regression was conducted to identify risk factors
36 associated with BG-EPVS and CSO-EPVS, and correlation analysis was employed to
37 explore the associations between different grades of BG-EPVS and CSO-EPVS with
38 CBF of the whole brain and specific regions of interest.

39 **Results:** The regression analysis revealed that BG-EPVS was associated with age
40 (odds ratio [OR]: 1.10, 95% confidence interval [CI]: 1.04–1.15), hypertension
41 (4.91, 1.55–15.6), and periventricular white matter hyperintensities (PVWMH)
42 (4.34, 1.46–12.95). Conversely, CSO-EPVS was linked to hypertension (4.40, 1.43–
43 13.57), drinking history (2.84, 1.08–7.45), sleep duration (2.01, 1.19–3.40), and
44 PVWMH (12.20, 3.83–38.85). Correlation analysis revealed a negative correlation
45 between BG-EPVS and the CBF of the whole brain ($r=-0.28$, $p=0.00$) and most brain
46 regions, except for the brain stem ($r=-0.19$, $p=0.05$). Conversely, CSO-EPVS was
47 negatively correlated with CBF of temporal lobe white matter ($r=-0.25$, $p=0.01$);
48 however, the significance was lost after FDR correction. CSO-EPVS was not

49 correlated with CBF across various brain regions.

50 **Conclusion:** Brain CBF decreased with the increasing severity of BG-EPVS,
51 suggesting that BG-EPVS could serve as an imaging marker for reflecting the changes
52 in brain CBF and an effective indicator for early ischemic stroke.

53

54 Keywords: enlarged perivascular spaces; basal ganglia; semiovale center; cerebral
55 blood flow; arterial spin labeling sequence

56

57 **Abbreviations**

58 EPVS: enlarged perivascular spaces

59 MRI: magnetic resonance imaging

60 BG: basal ganglia

61 CSO: centrum semiovale

62 CBF: cerebral blood flow

63 ASL: arterial spin labeling

64 CSVD: cerebral small vessel disease

65 WMH: white matter hyperintensities

66 TIA: transient ischemic attack

67 GUV: glial vascular unit

68 GMV: gray matter volume,

69 WMV: white matter volume

70 CSF: cerebrospinal fluid

71 **Introduction**

72 Perivascular spaces (PVS), also known as Virchow-Robin spaces, are fluid-filled
73 spaces around small arteries, capillaries, and venules in the brain parenchyma,
74 containing interstitial fluid and forming a network of excreting channels that remove
75 normal fluid and metabolic waste from the brain.¹ This is a crucial structure for
76 microvasculature, inflammation, immunodetection, and neuroinflammation, ensuring
77 proper maintenance and a stable neuronal environment.² PVS are considered
78 pathologic when sufficiently enlarged to be visible on magnetic resonance imaging
79 (MRI).³ For example, enlarged PVS, or enlarged perivascular spaces (EPVS), may
80 appear in all age groups and are visualized clearly on T2-weighted brain MRI.^{4,5}
81 These EPVS reflect glymphatic stasis secondary to the perivascular accumulation of
82 brain debris, although they may also represent an adaptive mechanism of the
83 glymphatic system to clear them.^{6,7} EPVS are most commonly observed in the
84 regions of the centrum semiovale and the basal ganglia;⁸ still, they have also been
85 identified in the hippocampal regions and frontal cortex. Nevertheless, the exact
86 mechanisms underlying the correlation of EPVS in adults are not fully understood.

87 Some studies have suggested that EPVS is one of the imaging manifestations of
88 cerebral small vessel disease (CSVD).⁹ In earlier studies, age,¹⁰ hypertension¹¹, and
89 white matter hyperintensities (WMH)¹² have been identified as risk factors for EPVS
90 in basal ganglia. Also, EPVS has been related to various age-related diseases and
91 neurodegenerative diseases, including brain injury,¹³ Alzheimer's disease,¹⁴
92 Parkinson's disease,¹⁵ multiple sclerosis,¹⁶ stroke or transient ischemic attack (TIA),¹⁷

93 microbleeds,¹⁸ and cognitive impairment.¹⁹ Moreover, studies have suggested that
94 EPVS may reflect the dysfunction of clearance of cerebrospinal fluid and metabolites
95 around cerebral small vessels and microvascular dysfunction.²⁰ Interestingly, it has
96 also been discovered that EPVS at different locations in the brain may have different
97 pathological mechanisms. E.g., EPVS in the basal ganglia (BG-EPVS) has been
98 associated with cerebral atrophy in stroke patients and atherosclerosis,^{10, 21} while
99 cerebrovascular amyloid deposition, resulting from impaired interstitial fluid drainage
100 has been associated with EPVS in centrum semiovale (CSO-EPVS).^{22,23} In addition,
101 studies predominantly comprising patients with a TIA/ischemic stroke indicated that
102 BG-EPVS but not CSO-EPVS are prognostic markers of stroke and death,
103 independent of other neuroimaging markers of small vessel disease.²⁴ Also, patients
104 with BG-EPVSs were found to be at an increased risk of recurrent ischemic stroke.²⁵
105 However, there is a lack of relevant research investigating the alterations in CBF
106 associated with EPVS.

107 This study aimed to quantitatively assess the relationship between EPVS and
108 brain CBF, obtained using arterial spin labeling sequences (ASL), which is a non-
109 invasive and cost-effective MRI technique for brain perfusion measurements.⁵ We
110 also investigated the potential effects of different levels of EPVS on brain CBF and
111 explored the possibility of using EPVS as an early imaging marker of changes in brain
112 CBF.

113

114 **Materials and Methods**

115 **Patients**

116 Patients treated at Longgang Center Hospital of Shenzhen between March 2023 and
117 May 2024 were recruited in the study. The inclusion criteria comprised those > 18
118 years old who have undergone cranial MRI and displayed different degrees of EPVS,
119 and their images met the diagnostic quality criteria. Exclusion criteria comprised
120 severe stenosis or occlusion of cerebral blood vessels, concurrent other vascular
121 diseases, history of traumatic brain injury, history of cerebral infarction, history of
122 cerebral hemorrhage, and other diseases or mental disorders that could cause cerebral
123 perfusion or metabolic abnormalities. Also, data with poor image quality were
124 excluded from the analysis.

125 The Ethics Committee of the Longgang Central Hospital of Shenzhen approved
126 this cross-sectional study. All participants provided written informed consent.

127 **Demographic and clinical data**

128 We recorded basic demographic data (age, sex, height, weight, alcohol consumption,
129 and smoking) as well as medical and treatment data (hypertension, diabetes,
130 hyperlipidemia, coronary heart disease). Sleep time was recorded as < 6 hours, 6-8
131 hours, and > 8 hours. Corresponding info was also obtained from medical imaging
132 data.

133 **MRI Data Acquisition**

134 MR imaging was acquired on the 3.0 T Prisma Siemens scanner. The parameters were
135 as follows: T1 weight imaging (T1WI): TR=250ms, TE=2.5ms, thickness=5mm, FOV
136 =220×220mm², acquisition matrix=320×288; T2 weight imaging (T2WI):

137 TR=4000ms, TE=94ms, thickness=5mm, field of view (FOV)=220×220mm²,
138 acquisition matrix=320 × 320; fluid-attenuated inversion recovery (FLAIR):
139 TR=8000 ms, TE=84 ms, thickness=5.0 mm, FOV=220×220 mm², acquisition
140 matrix=320×224; Diffusion weight imaging (DWI): TR=3300ms, TE=54 ms,
141 thickness=5 mm, FOV=220×220 mm², acquisition matrix=160×160; ASL: TR=4600
142 ms, TE=16.1 ms, thickness=3.0 mm, FOV=220×220 mm², Reconstruction
143 matrix=64×64, post labeling delay = 2000 ms; T1-MPRAGE (high-resolution T1WI
144 for evaluating brain structure) are as follows: TR =2300ms, TE=2.2ms, thickness=1.0
145 mm, FOV=256×256 mm, acquisition matrix 256×256.

146 **EPVS assessment**

147 EPVS were defined as cerebrospinal fluid-like signal intensity (hypointense on T1
148 and hyperintense on T2) lesions in areas supplied by perforating arteries. Those
149 parallel to the imaging plane appeared round and ovoid, and those perpendicular to it
150 appeared linear; their maximum diameter was 3 mm. EPVS were counted in the BG
151 and CSO using the following rating scale: grade 0 = 0 EPVS, grade 1 = 1–10 EPVS,
152 grade 2 = 11–20 EPVS, grade 3 = 21–40 EPVS, and grade 4 => 40 EPVS in each
153 brain region, see Figure 1. For the BG, we excluded perforated substances at the level
154 and below the anterior commissure, as most people have EPVS in this area.²⁶ The
155 numbers referred to EPVS on one side of the brain: after reviewing all relevant slices
156 for the assessed anatomical area, the slice and side with the highest number of EPVS
157 were recorded.²⁷

158 Two trained physicians with > 5 years of experience evaluated the EPVS grade.

159 Both neurologists discussed any inconsistencies between the reported results until a
160 consensus was reached.

161 **Fazekas Scale for White Matter Hyperintensities**

162 Fazekas scale was used for white matter hyperintensities (WMH) in both
163 periventricular (PVWMH) and deep white matter (DWMH).²⁸ PVWMH was graded
164 as follows: 0 = absence, 1 = caps or pencil-thin lining, 2 = smooth halo, and 3 =
165 irregular. DWMH were rated as follows: 0 = absence, 1 = punctate foci, 2 = beginning
166 confluence of foci, and 3 = large confluent areas.

167 **Extraction of CBF and Segmentation**

168 Figure 2. ASL data were preprocessed and analyzed using Matlab (SPM 12) software.
169 The main analysis steps were as follows: (1) the labeling map of the ASL image was
170 registered to 3D T1 images; (2) 3D T1 images were segmented by NewSegment and
171 registered to the standard Montreal Neurological Institute (MNI) space; (3) CBF
172 obtained from ASL was written into MNI space according to T1 image registration
173 parameters. The CBF values of the whole brain and local brain regions were extracted
174 based on ROI. The gray matter volume (GMV), white matter volume (WMV),
175 cerebrospinal fluid (CSF) volume, and corresponding volume proportions were
176 simultaneously obtained during the segmentation stage.

177 **Statistical analysis**

178 Statistical Package for Social Sciences (SPSS version 26) was used for statistical
179 analyses. Categorical and continuous variables with non-normal distribution were
180 summarized as counts (percentage) and the means (standard deviation, SD) or

181 medians (interquartile ranges, IQR), respectively. Logistic regression was conducted
182 to identify risk factors associated with BG-EPVS and CSO-EPVS. Correlation
183 analysis was employed to explore the associations between different grades of BG-
184 EPVS and CSO-EPVS with CBF of the whole brain and specific regions of interest.
185 The correlation analysis was adjusted for age, gender, hypertension, diabetes,
186 hyperlipidemia, coronary heart disease, smoking, drinking, sleep duration, WMH, and
187 brain volume. p values of correlation analysis were corrected using the false discovery
188 rate (FDR) method with a significance threshold set at 0.05.

189

190 **Results**

191 **Participants characteristics**

192 A total of 109 individuals, 55 men and 54 women, with a mean age of 47.1 ± 12.2 ,
193 were included in the analysis. Participants' characteristics are summarized in Table 1.
194 Regarding the different BG-EPVS grades, there were 15 cases of grade 0, 22 cases of
195 grade 1, 29 cases of grade 2, 28 cases of grade 3, and 15 cases of grade 4, respectively.
196 Concerning the severity of CSO-EPVS, there were 15 cases of grade 0, 26 cases of
197 grade 1, 34 cases of grade 2, 21 cases of grade 3, and 13 cases of grade 4.

198 **Factors associated with BG-EPVS and CSO-EPVS**

199 Table 2 presents the results of the multivariate analysis comparing clinical and
200 neuroimaging features between BG-EPVS and CSO-EPVS. Regression analysis
201 revealed that BG-EPVS was associated with factors such as age ((odds ratio [OR]:
202 1.10, 95% confidence interval [CI]: 1.04–1.15), hypertension (4.91, 1.55–15.6), and

203 PVWMH (4.34,1.46–12.95). Conversely, CSO-EPVS was linked to hypertension
204 (4.40,1.43–13.57), drinking history (2.84,1.08–7.45), sleep duration (2.01,1.19–3.40),
205 and PVWMH (12.20,3.83–38.85).

206 **Association between EPVS and CBF of different brain regions**

207 The CBF values of the whole brain and various brain regions in BG-EPVS and CSO-
208 EPVS are presented in Figure 3 and Figure 4, respectively. As shown in Figure 3, as
209 the severity of BG-EPVS increased, there was a downward trend in the CBF values in
210 specific brain regions. However, with the increasing severity of CSO-EPVS showed
211 in Figure 4, no significant trend in the changes was observed in some brain regions.
212 The specific CBF values of each brain regions with different degrees of EPVS are
213 shown in S1 and S2.

214 The distribution of P-values corrected with FDR is shown in Figure 5. Correlation
215 analysis revealed that BG-EPVS was negatively correlated with the whole brain ($r=-$
216 0.28 , $p=0.00$) and most brain regions, except for the brain stem ($r=-0.19$, $p=0.05$). On
217 the other hand, CSO-EPVS showed a negative correlation with temporal lobe white
218 matter ($r=-0.25$, $p=0.01$); however, this result was no longer significant after FDR
219 correction. Furthermore, CSO-EPVS showed no correlation with CBF across various
220 brain regions. Unadjusted p values are presented in S3 and S4.

221

222 **Discussion**

223 EPVS are most commonly observed in the regions of the centrum semiovale (CSO)
224 and the basal ganglia (BG). In the present study, we quantitatively evaluated CBF

225 changes at different levels of BG-EPVS and CSO-EPVS. Our results revealed that as
226 the severity of BG-EPVS increased, there was a decrease in CBF of the whole brain
227 and almost all regions, which showed a negative correlation, whereas no such
228 phenomenon was observed with CSO-EPVS following the adjustment for multiple
229 factors. In the whole cohort, we identified different risk factors for various locations
230 of EPVS. Age, hypertension, and PVWMH resulted as risk factors for BG-EPVS,
231 while hypertension, smoking, sleep duration, and PVWMH were associated with
232 CSO-EPVS. Our results revealed the correlation between varying degrees of EPVS
233 and changes in brain CBF. The BG-EPVS, rather than CSO EPVS, induced
234 corresponding alterations in brain CBF. Therefore, BG-EPVS could be a potential
235 imaging marker for monitoring CBF and an early imaging indicator for ischemic
236 stroke.

237 Evidence indicates that the PVS eliminates soluble waste from the brain.^{29, 30} The
238 pathologic mechanism of PVS is not yet fully understood, and current studies have
239 highlighted the important role of aquaporin-4 (AQP4)-lined PVS, cerebrovascular
240 pulsation, and metabolite clearance in normal central nervous system physiology.^{20,31}
241 Our results show the effective removal of waste products in the brain, including A β
242 and tau, that accumulate in late-onset Alzheimer's disease, thereby potentially
243 accelerating vascular A β accumulation and perpetuating a detrimental cycle of
244 perivascular clearance dysfunction.^{32,33} The microstructural anatomy, MRI
245 enhancement, physiology, and fluid dynamics of PVS are crucial in neurobiology.
246 Nevertheless, certain studies indicate that BG-EPVS and CSO-EPVS may be

247 associated with distinct pathological mechanisms.³⁴

248 We observed that as the severity of BG-EPVS increased, a decrease in brain CBF
249 occurred, leading us to speculate that the primary pathogenesis may be associated
250 with atherosclerotic disease. Previous literature reported that BG-EPVS is an imaging
251 biomarker associated with hypertensive arterial disease and arterial stiffness.³⁵ Arterial
252 stiffness is a characteristic feature of aging that may contribute to the EPVS
253 development in the basal ganglia.^{21,36} This could be attributed to the impact of high
254 pulse waves and restoration of damaged blood vessel walls, making the basal ganglia
255 area more susceptible to damage than other regions. Furthermore, decreased elasticity
256 and thickening of the vessel impair the contractile phenotype of smooth muscle cells,
257 leading to reduced brain CBF.^{4,30} These could also cause alterations in the diameter
258 and structure of small blood vessels, which in turn impairs fluid dynamics.³² All these
259 structural changes ultimately lead to the expansion of the perivascular space, forming
260 a pathological state.³³

261 Alterations in the relationship between EPVS and CBF may be ascribed to
262 regulating the glial-vascular unit (GVU), which comprises glial cells (astrocytes and
263 microglia) and perivascular cells (endothelial cells, pericytes, and perivascular
264 macrophages). The neurovascular unit (NVU) is widely acknowledged for its utility in
265 investigating intricate interactions among multicellular structures.³⁷ These cells
266 collaborate to uphold central nervous system (CNS) homeostasis and execute diverse
267 physiological functions. The interplay between glial cells and perivascular cells
268 within the PVS microenvironment promotes the effective execution of multiple

269 functions, including CBF regulation, angiogenesis, blood-brain barrier (BBB)
270 integrity maintenance, and neurotoxic waste clearance through the glymphatic
271 system.³⁸ Some researchers have posited that GVU is a nexus for integrating
272 neurovascular, neuroimmune, and neurodegenerative mechanisms after brain injury
273 and during wound healing.³⁹ Consequently, the heightened severity of EPVS impairs
274 overall GVU function, leading to more pronounced changes in the cerebral
275 vasculature, specifically reduced CBF, which is somewhat consistent with our results.
276 Our findings indicated that the alteration in CBF was specifically linked to BG-EPVS
277 rather than CSO-EPVS, thus implying that the damage caused by CSO-EPVS may be
278 entering a compensatory phase or not primarily affecting the function of vascular
279 component units, thereby allowing GVU's regulation of CBF to remain unaffected.
280 Nevertheless, further investigation is warranted.

281 In a study of patients with spontaneous intracerebral hemorrhage, the presence of
282 severe CSO-EPVS served as an indicator of vascular amyloid burden that was helpful
283 in the diagnosis of cerebral amyloid angiopathy, unlike BG-EPVS, thus suggesting
284 that the spatial distribution of EPVS could reflect underlying cerebrovascular
285 pathology.⁴⁰ Abnormal protein aggregation, such as β -amyloid, can obstruct the
286 upstream cortical artery system, impairing cerebrospinal fluid drainage and
287 enlargement of the perivascular space.⁸ White matter exhibits lower cell density and
288 greater susceptibility to stress than gray matter, which may contribute to the formation
289 mechanism of CSO-EPVS.⁴ Two independent prospective cohort studies from the
290 United Kingdom and China, primarily including patients TIA or ischemic stroke,

291 demonstrated that BG-EPVS, rather than CSO-EPVS, serve as prognostic markers for
292 stroke and mortality, independent of other neuroimaging markers of CSVD.²⁵ Our
293 findings are consistent with this, indicating that the severity of CSO-EPVS is not
294 significantly correlated with changes in CBF and that CSO-EPVS may not serve as an
295 imaging marker for early ischemic stroke.

296 There are relatively few risk factors associated with EPVS. A previous study
297 demonstrated that age, hypertension, and WMH were the primary influencing factors
298 of BG-EPVS,⁴¹ which is in line with our findings. Some studies have also indicated
299 that in addition to gender, age, obesity, and other influencing factors, EPVS was
300 associated with cognitive dysfunction and WMH.¹⁹ Our results revealed that
301 hypertension, drinking, sleep duration, and PVWMH were all correlated with CSO-
302 EPVS, contradicting some existing literature. For example, Yamasaki et al. identified
303 no specific risk factors related to CSO-EPVS, possibly due to differences in the
304 included population and an age limit of 40 years old.³⁸ Previous research has shown
305 that EPVS could lead to microdamage in the white matter of the brain, which is
306 closely tied to WMH. EPVS and WMH may share common pathogenic mechanisms
307 associated with interstitial fluid leakage, microvascular wall dysfunction, and vascular
308 inflammation.^{39,40} While it has been reported that neuronal atrophy may cause EPVS
309 in the basal ganglia, we found no correlation between EPVS and brain volume.
310 Current research results present inconsistencies requiring further investigation.⁹ Other
311 studies have suggested associations between EPVS, breathing patterns, sleep quality,
312 and weight management.⁴² The current literature reports different results on the risk

313 factors related to EPVS; in short, there is a possibility that a combination of hitherto
314 unknown environmental and genetic factors may be at play.⁴³

315 The present study has several limitations. Firstly, as this is a single-center study
316 with a limited sample size, future research should focus on extending to multiple
317 centers rather than just increasing the sample size. Secondly, the brain CBF exhibits
318 continuous fluctuations despite our efforts to maintain subjects' calmness.
319 Consequently, it is challenging to obtain completely accurate and consistent
320 measurements of blood flow. Thirdly, setting the post-label delay (PLD) parameters in
321 the ASL sequence may have specific effects on quantitative CBF values. Also, when
322 choosing the region of interest (ROI), it is unclear whether alternative options, such as
323 functional partitioning, would yield meaningful results based on the analysis of brain
324 anatomical structure.

325

326 **Conclusion**

327 Our data indicated that BG-EPVS, rather than CSO-EPVS, was negatively
328 correlated with CBF across the whole brain and almost all brain regions. Also, CBF
329 decreased with the increasing severity of BG-EPVS, suggesting that BG-EPVS could
330 serve as an imaging marker for reflecting the changes of brain CBF and an effective
331 indicator for early ischemic stroke.

332

333 **Acknowledgments**

334 We are deeply grateful to our patients and their families for their enthusiastic

335 participation in our study and to the staff of Longgang Central Hospital for their
336 assistance in conducting medical interviews and obtaining clinical data.

337 **Funding**

338 This research has no funding support.

339 **Disclosures**

340 None.

341

342 **References**

- 343 1. Brown R, Benveniste H, Black SE, Charpak S, Dichgans M, Joutel A,
344 Nedergaard M, Smith KJ, Zlokovic B V., Wardlaw JM. Understanding the role of the
345 perivascular space in cerebral small vessel disease. *Cardiovascular Research*.
346 2018;114:1462–1473. doi:10.1093/cvr/cvy113
- 347 2. Ineichen B V., Okar S V., Proulx ST, Engelhardt B, Lassmann H, Reich DS.
348 Perivascular spaces and their role in neuroinflammation. *Neuron*. 2022;110:3566–
349 3581. doi:10.1016/j.neuron.2022.10.024
- 350 3. Bown CW, Carare RO, Schrag MS, Jefferson AL. Physiology and Clinical
351 Relevance of Enlarged Perivascular Spaces in the Aging Brain. *Neurology*.
352 2022;98:107–117. doi:10.1212/WNL.0000000000013077
- 353 4. Shulyatnikova, Tatyana, and Melvin R Hayden. Why Are Perivascular Spaces
354 Important? *Medicina* (Kaunas, Lithuania) 59(5), 917. doi:10.3390/medicina59050917
- 355 5. Potter GM, Chappell FM, Morris Z, Wardlaw JM. Cerebral perivascular spaces
356 visible on magnetic resonance imaging: Development of a qualitative rating scale and

- 357 its observer reliability. *Cerebrovascular Diseases*. 2015;39:224–231.
358 doi:10.1159/000375153
- 359 6. Kim JY, Nam Y, Kim S, Shin NY, Kim HG. MRI-visible Perivascular Spaces in
360 the Neonatal Brain. *Radiology*. 2023;307. doi:10.1148/radiol.221314
- 361 7. Troili F, Cipollini V, Moci M, Morena E, Palotai M, Rinaldi V, Romano C, Ristori
362 G, Giubilei F, Salvetti M, et al. Perivascular Unit: This Must Be the Place. The
363 Anatomical Crossroad Between the Immune, Vascular and Nervous System. *Frontiers*
364 *in Neuroanatomy*. 2020;14. doi:10.3389/fnana.2020.00017
- 365 8. Duering M, Biessels GJ, Brodtmann A, Chen C, Cordonnier C, de Leeuw FE,
366 Debette S, Frayne R, Jouvent E, Rost NS, et al. Neuroimaging standards for research
367 into small vessel disease—advances since 2013. *The Lancet Neurology*. 2023;22:602–
368 618. doi:10.1016/S1474-4422(23)00131-X
- 369 9. Potter GM, Doubal FN, Jackson CA, Chappell FM, Sudlow CL, Dennis MS,
370 Wardlaw JM. Enlarged perivascular spaces and cerebral small vessel disease.
371 *International Journal of Stroke*. 2015;10:376–381. doi:10.1111/ijvs.12054
- 372 10. Yang Y, Wang M, Luan M, Song X, Wang Y, Xu L, Zhong M, Zheng X. Enlarged
373 Perivascular Spaces and Age-Related Clinical Diseases. *Clinical Interventions in*
374 *Aging*. 2023;18:855–867. doi:10.2147/CIA.S404908
- 375 11. Zou Q, Wang M, Wei X, Li W. Prevalence and Risk Factors for Enlarged
376 Perivascular Spaces in Young Adults from a Neurology Clinic-Based Cohort. *Brain*
377 *Sciences*. 2022;12. doi:10.3390/brainsci12091164
- 378 12. Zou Q, Wang M, Zhang D, Wei X, Li W. White Matter Hyperintensities in Young

- 379 Patients from a Neurological Outpatient Clinic: Prevalence, Risk Factors, and
380 Correlation with Enlarged Perivascular Spaces. *Journal of Personalized Medicine*.
381 2023;13. doi:10.3390/jpm13030525
- 382 13. Hicks A, Sinclair B, Shultz S, Pham W, Silbert LC, Schwartz DL, Rowe CC,
383 Ponsford JL, Law M, Spitz G. Associations of Enlarged Perivascular Spaces With
384 Brain Lesions, Brain Age, and Clinical Outcomes in Chronic Traumatic Brain Injury.
385 *Neurology*. 2023;10.1212. doi:10.1212/WNL.0000000000207370
- 386 14. Lynch M, Pham W, Sinclair B, O'Brien TJ, Law M, Vivash L. Perivascular
387 spaces as a potential biomarker of Alzheimer's disease. *Frontiers in Neuroscience*.
388 2022;16:1–16. doi:10.3389/fnins.2022.1021131
- 389 15. Cao X, Gan C, Zhang H, Yuan Y, Sun H, Zhang L, Wang L, Zhang L, Zhang K.
390 Altered perivascular spaces in subcortical white matter in Parkinson's disease patients
391 with levodopa-induced dyskinesia. *npj Parkinson's Disease*. 2024;10:1–9.
392 doi:10.1038/s41531-024-00688-0
- 393 16. Kolbe SC, Garcia LM, Yu N, Boonstra FM, Clough M, Sinclair B, White O, van
394 der Walt A, Butzkueven H, Fielding J, et al. Lesion Volume in Relapsing Multiple
395 Sclerosis is Associated with Perivascular Space Enlargement at the Level of the Basal
396 Ganglia. *American Journal of Neuroradiology*. 2022;43:238–244.
397 doi:10.3174/ajnr.A7398
- 398 17. Tian Y, Wang M, Pan Y, Meng X, Zhao X, Liu L, Wang Y, Wang Y. In patients
399 who had a stroke or TIA, enlarged perivascular spaces in basal ganglia may cause
400 future haemorrhagic strokes. *Stroke and Vascular Neurology*. 2023;9:8–17.

- 401 doi:10.1136/svn-2022-002157
- 402 18. Wang X, Feng H, Wang Y, Zhou J, Zhao X. Enlarged perivascular spaces and
403 cerebral small vessel disease in spontaneous intracerebral hemorrhage patients.
404 *Frontiers in Neurology*. 2019;10:1–9. doi:10.3389/fneur.2019.00881
- 405 19. Libecap TJ, Zachariou V, Bauer CE, Wilcock DM, Jicha GA, Raslau FD, Gold
406 BT. Enlarged Perivascular Spaces Are Negatively Associated With Montreal
407 Cognitive Assessment Scores in Older Adults. *Frontiers in Neurology*. 2022;13:8–13.
408 doi:10.3389/fneur.2022.888511
- 409 20. Mestre H, Kostrikov S, Mehta RI, Nedergaard M. Perivascular spaces,
410 glymphatic dysfunction, and small vessel disease. *Clinical Science*. 2017;131:2257–
411 2274. doi:10.1042/CS20160381
- 412 21. Zhang X, Ding L, Yang L, Qin W, Yuan J, Li S, Hu W. Brain atrophy correlates
413 with severe enlarged perivascular spaces in basal ganglia among lacunar stroke
414 patients. *PLoS ONE*. 2016;11:1–9. doi:10.1371/journal.pone.0149593
- 415 22. Riba-Llena I, Jiménez-Balado J, Castañé X, Girona A, López-Rueda A, Mundet
416 X, Jarca CI, Álvarez-Sabin J, Montaner J, Delgado P. Arterial stiffness is associated
417 with basal ganglia enlarged perivascular spaces and cerebral small vessel disease load.
418 *Stroke*. 2018;49:1279–1281. doi:10.1161/STROKEAHA.118.020163
- 419 23. Sacchi L, Arcaro M, Carandini T, Pietroboni AM, Fumagalli GG, Fenoglio C,
420 Serpente M, Sorrentino F, Visconte C, Pintus M, et al. Association between enlarged
421 perivascular spaces and cerebrospinal fluid aquaporin-4 and tau levels: report from a
422 memory clinic. *Frontiers in Aging Neuroscience*. 2023;15:1–6.

423 doi:10.3389/fnagi.2023.1191714

424 24. Charidimou A, Jaunmuktane Z, Baron J-C, Burnell M, Varlet P, Peeters A,
425 Xuereb J, Jäger R, Brandner S, Werring DJ. White matter perivascular spaces.
426 *Neurology*. 2014;82:57–62. doi:10.1212/01.wnl.0000438225.02729.04

427 25. Liang Y, Deng M, Chen YK, Mok V, Wang DF, Ungvari GS, Chu CWW, Berge E,
428 Tang WK. Enlarged perivascular spaces are associated with health-related quality of
429 life in patients with acute ischemic stroke. *CNS Neuroscience and Therapeutics*.
430 2017;23:973–979. doi:10.1111/cns.12766

431 26. Banerjee G, Kim HJ, Fox Z, Jäger HR, Wilson D, Charidimou A, Na HK, Na DL,
432 Seo SW, Werring DJ. MRI-visible perivascular space location is associated with
433 Alzheimer’s disease independently of amyloid burden. *Brain*. 2017;140:1107–1116.
434 doi:10.1093/brain/awx003

435 27. Rivera-Rivera LA, Schubert T, Turski P, Johnson KM, Berman SE, Rowley HA,
436 Carlsson CM, Johnson SC, Wieben O. Changes in intracranial venous blood flow and
437 pulsatility in Alzheimer’s disease: A 4D flow MRI study. *Journal of Cerebral Blood*
438 *Flow and Metabolism*. 2017;37:2149–2158. doi:10.1177/0271678X16661340

439 28. Kim JS, Lee S, Kim GE, Oh DJ, Moon W, Bae J Bin, Han JW, Byun S, Suh SW,
440 Choi YY, et al. Construction and validation of a cerebral white matter hyperintensity
441 probability map of older Koreans. *NeuroImage: Clinical*. 2021;30:102607. doi:
442 10.1016/j.nicl.2021.102607

443 29. Gouveia-Freitas K, Bastos-Leite AJ. Perivascular spaces and brain waste
444 clearance systems: relevance for neurodegenerative and cerebrovascular pathology.

- 445 *Neuroradiology*. 2021;63:1581–1597. doi:10.1007/s00234-021-02718-7
- 446 30. Tian Y, Cai X, Zhou Y, Jin A, Wang S, Yang Y, Mei L, Jing J, Li S, Meng X, et al.
447 Impaired glymphatic system as evidenced by low diffusivity along perivascular
448 spaces is associated with cerebral small vessel disease: A population-based study.
449 *Stroke and Vascular Neurology*. 2023;8:413–423. doi:10.1136/svn-2022-002191
- 450 31. Szczygielski J, Kopańska M, Wysocka A, Oertel J. Cerebral Microcirculation,
451 Perivascular Unit, and Glymphatic System: Role of Aquaporin-4 as the Gatekeeper
452 for Water Homeostasis. *Frontiers in Neurology*. 2021;12:1–18.
453 doi:10.3389/fneur.2021.767470
- 454 32. Kiviniemi V, Wang X, Korhonen V, Keinänen T, Tuovinen T, Autio J, Levan P,
455 Keilholz S, Zang YF, Hennig J, et al. Ultra-fast magnetic resonance encephalography
456 of physiological brain activity-Glymphatic pulsation mechanisms? *Journal of*
457 *Cerebral Blood Flow and Metabolism*. 2016;36:1033–1045.
458 doi:10.1177/0271678X15622047
- 459 33. Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in
460 neurological disorders. *The Lancet Neurology*. 2018;17:1016–1024.
461 doi:10.1016/S1474-4422(18)30318-1
- 462 34. Charidimou A, Hong YT, Jäger HR, Fox Z, Aigbirhio FI, Fryer TD, Menon DK,
463 Warburton EA, Werring DJ, Baron JC. White Matter Perivascular Spaces on Magnetic
464 Resonance Imaging: Marker of Cerebrovascular Amyloid Burden? *Stroke*.
465 2015;46:1707–1709. doi:10.1161/STROKEAHA.115.009090
- 466 35. Wardlaw JM, Benveniste H, Nedergaard M, Zlokovic B V., Mestre H, Lee H,

- 467 Doubal FN, Brown R, Ramirez J, MacIntosh BJ, et al. Perivascular spaces in the brain:
468 anatomy, physiology and pathology. *Nature Reviews Neurology*. 2020;16:137–153.doi:
469 10.1038/s41582-020-0312-z
- 470 36. Bown CW, Khan OA, Liu D, Remedios SW, Pechman KR, Terry JG, Nair S,
471 Davis LT, Landman BA, Gifford KA, et al. Enlarged perivascular space burden
472 associations with arterial stiffness and cognition. *Neurobiology of Aging*.
473 2023;124:85–97. doi:10.1016/j.neurobiolaging.2022.10.014
- 474 37. Raposo N, Planton M, Payoux P, Péran P, Albucher JF, Calviere L, Viguier A,
475 Rousseau V, Hitzel A, Chollet F, et al. Enlarged perivascular spaces and florbetapir
476 uptake in patients with intracerebral hemorrhage. *European Journal of Nuclear
477 Medicine and Molecular Imaging*. 2019;46:2339–2347. doi:10.1007/s00259-019-
478 04441-1
- 479 38. Yamasaki T, Ikawa F, Ichihara N, Hidaka T, Matsuda S, Ozono I, Chiku M,
480 Kitamura N, Hamano T, Horie N, et al. Factors associated with the location of
481 perivascular space enlargement in middle-aged individuals undergoing brain
482 screening in Japan. *Clinical Neurology and Neurosurgery*. 2022;223:107497. doi:
483 10.1016/j.clineuro.2022.107497
- 484 39. Zhu YC, Dufouil C, Mazoyer B, Soumaré A, Ricolfi F, Tzourio C, Chabriat H.
485 Frequency and location of dilated Virchow-Robin spaces in elderly people: A
486 population-based 3D MR imaging study. *American Journal of Neuroradiology*.
487 2011;32:709–713. doi:10.3174/ajnr.A2366
- 488 40. Jian X, Xu F, Yang M, Zhang M, Yun W. Correlation between enlarged

489 perivascular space and brain white matter hyperintensities in patients with recent
490 small subcortical infarct. *Brain and Behavior*. 2023;1–9. doi:10.1002/brb3.3168

491 41. Zhu YC, Tzourio C, Soumaré A, Mazoyer B, Dufouil C, Chabriat H. Severity of
492 dilated virchow-robin spaces is associated with age, blood pressure, and MRI markers
493 of small vessel disease: A population-based study. *Stroke*. 2010;41:2483–2490.
494 doi:10.1161/STROKEAHA.110.591586

495 42. Opel RA, Christy A, Boespflug EL, Weymann KB, Case B, Pollock JM, Silbert
496 LC, Lim MM. Effects of traumatic brain injury on sleep and enlarged perivascular
497 spaces. *Journal of Cerebral Blood Flow and Metabolism*. 2019;39:2258–2267.
498 doi:10.1177/0271678X18791632

499 43. Kim HG, Shin NY, Nam Y, Yun E, Yoon U, Lee HS, Ahn KJ. MRI-visible Dilated
500 Perivascular Space in the Brain by Age: The Human Connectome Project. *Radiology*.
501 2023;306:e213254. doi:10.1148/radiol.213254

502

503

504

505

506

507 **Figure Legends**

508 Figure 1. Representative MR images of EPVS burden across severity categories. Panels (a) to (e)
509 show axial T2 MR brain images at the level of the basal ganglia. Panels (f) to (j) show axial T2
510 MR brain images at the level of the centrum semiovale. Arrows denote individual EPVS. Columns
511 are ordered left to right in increasing bins of EPVS burden (0,1–10, 11–20, 21–40, 41+).

512

513 Figure 2 The schematic diagram of the process of extracting cerebral blood flow of brain region
514 interest ((a)-(e)). Note that the images do not represent the corresponding results displayed.

515

516 Figure 3. The variations of cerebral blood flow (CBF) across brain regions with varying degrees of
517 BG-EPVS. The x-axis represented the BG-EPVS grade, and the y-axis denoted the CBF values for
518 each specific brain region. Icons (such as triangles and squares) represented the mean CBF, and
519 the dashed lines above and below represented the standard error of the mean CBF.

520

521 Figure 4. The variations of cerebral blood flow (CBF) across brain regions with varying degrees of
522 CSO-EPVS. The x-axis represented the CSO-EPVS grade, and the y-axis denoted the CBF values
523 for each specific brain region. Icons (such as triangles and squares) represented the mean CBF,
524 and the dashed lines above and below represented the standard error of the mean CBF.

525

526 Figure 5. The magnitude of the r correlation coefficient and p values between the different severity
527 of EPVS located in the basal ganglia and semioval center and brain regional cerebral blood flow.

528

529 **Tables**

530

Table 1. Patient characteristics

Demographic data	N=109
Age, mean (SD)	47.1±12.2
Sex, male, n (%)	55(50.5)
History of hypertension, n (%)	26(23.9)
Diabetes, n (%)	11(10.2)
Hyperlipidemia, n (%)	17(15.6)
Coronary heart disease, n (%)	4(3.7)
Smoking history, n (%)	21(19.3)
Drinking history, n (%)	28(25.7)
BMI, mean (SD)	23.8±3.7
Sleep duration(hours), n (%)	
<6h	36(33.0)
6-8h	41(37.6)
>8h	32(29.4)
BG-EPVS, n (%)	
0	15(13.8)
1	22(20.2)
2	29(26.6)
3	28(25.7)
4	15(13.8)
CSO-EPVS, n (%)	
0	15(13.8)
1	26(23.9)
2	34(31.2)
3	21(19.3)
4	13(11.1)
PVWMH grade, n (%)	
0	61(56.0)
1	34(31.2)
2	12(11.0)
3	2(1.8)
DWMH grade, n (%)	
0	55(50.5)
1	41(37.6)
2	10(9.2)
3	3(2.8)
GMV, mean (SD)	661.6±64.3
WMV, mean (SD)	493.3±71.9
CSF, median (IQR)	222.0(195.5-250.0)
TIV mean (SD)	1384.9±145.7

GMVf, median (IQR)	0.48(0.46-0.50)
WMVf, median (IQR)	0.36(0.34-0.37)

531 Note: PVWMH: Periventricular white matter hyperintensities; DWMH: Deep white matter hyperi
 532 ntensities. GMV: Gray matter volume, WMV: White matter volume, CSF: cerebrospinal fluid, TIV:
 533 Total intracranial volume, GMVf: Gray matter volume fraction, WMVf: White matter volume
 534 fraction, SD: standard deviation, IQR: interquartile range.

535

536 **Table 2. Multivariable ordinal logistic regression analysis showing predictors of**

537 **increased basal ganglia and centrum semiovale EPVS severity**

	BG-EPVS		CSO-EPVS	
	OR (95% CI)	P value	OR (95% CI)	P value
Age	1.10(1.04-1.15)	0.00	1.03(0.98-1.08)	0.21
Sex, Male	0.58(0.19-1.76)	0.33	0.40(0.13-1.22)	0.11
History of hypertension	4.91(1.55-15.6)	0.01	4.40(1.43-13.57)	0.01
Diabetes	0.75(0.18-3.16)	0.70	0.50(0.12-1.98)	0.32
Coronary heart disease	4.63(0.32-66.2)	0.26	3.99(0.39-40.95)	0.25
Hyperlipidemia	0.47(0.14-1.52)	0.21	0.96(0.31-3.02)	0.95
Smoking history	1.10(0.39-3.13)	0.85	1.44(0.51-4.07)	0.49
Drinking history	2.65(1.00-6.99)	0.05	2.84(1.08-7.45)	0.03
BMI	1.09(0.96-1.23)	0.19	1.01(0.89-1.14)	0.92
Sleep duration(hours)	1.11(0.66-1.87)	0.69	2.01(1.19-3.40)	0.01
PVWMH	4.34(1.46-12.95)	0.01	12.20(3.83-38.85)	0.00
DWMH	1.47(0.53-4.03)	0.46	1.15(0.42-3.26)	0.78
GMV	1.72(0.80-3.67)	0.16	1.32(0.62-2.76)	0.47
WMV	1.71(0.80-3.65)	0.17	1.3(0.61-2.76)	0.49
CSF	1.69(0.79-3.58)	0.18	1.21(0.57-2.60)	0.62
TIV	0.58(0.27-1.24)	0.16	0.78(0.36-1.64)	0.50

538 Note: PVWMH: Periventricular white matter hyperintensities; DWMH: Deep white matter
 539 hyperintensities. GMV: Gray matter volume, WMV: White matter volume, CSF: cerebrospinal
 540 fluid, TIV: Total intracranial volume, GMVf: Gray matter volume fraction, WMVf: White matter
 541 volume fraction.









